GlassScriptPhysician profile
Stacey D Goodrich
NPI 1578570180
$729.58
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $325 · 2020: $153 · 2021: $215 · 2022: $36.75.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $427.43 | 2019-2022 | |
| Amarin Pharma, INC. | $54.47 | 2021 | |
| Novo Nordisk INC | $53.21 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.03 | 2020-2021 | |
| Philips North America LLC | $33.74 | 2019 | |
| Pfizer INC. | $26.44 | 2019 | |
| Janssen Pharmaceuticals, INC | $25.03 | 2019-2020 | |
| Astellas Pharma US INC | $14.94 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.55 | 2019 | |
| Abbvie INC. | $12.27 | 2021 | |
| Novartis Pharmaceuticals Corporation | $11.76 | 2021 | |
| Lilly USA, LLC | $11.71 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacey Goodrich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.